Scinai Immunotherapeutics (SCNI) Cash from Financing Activities (2019 - 2024)

Scinai Immunotherapeutics has disclosed Cash from Financing Activities across 5 years of filings, most recently posting $2.0 million for Q4 2024.

• Cash from Financing Activities for Q4 2024 came in at $2.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $1.5 million (down 79.26% YoY), and the FY2025 annual result was $5.8 million, up 67.68% from the prior year.
• Cash from Financing Activities came in at $2.0 million for Q4 2024 at Scinai Immunotherapeutics, up from $8000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $12.5 million in Q1 2021 to a low of -$988000.0 in Q3 2021.
• The 4-year median for Cash from Financing Activities is -$66000.0 (2020), against an average of $3.1 million.
• Peak annual rise in Cash from Financing Activities reached 2946.79% in 2021, while the deepest fall reached 605.71% in 2021.
• Scinai Immunotherapeutics' Cash from Financing Activities stood at -$312000.0 in 2020, then soared by 2946.79% to $8.9 million in 2021, then plunged by 105.27% to -$468000.0 in 2022, then soared by 527.35% to $2.0 million in 2024.
• The last three Cash from Financing Activities figures came in at $2.0 million (Q4 2024), $8000.0 (Q3 2024), and -$468000.0 (Q2 2022), per Business Quant data.